Codexis (CDXS) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Codexis is set to announce its Q2 2025 earnings on August 13, expecting a loss of ($0.17) per share and revenue of $14.18 million.
• The company recently reported a negative return on equity of 118.47% and a net margin of 149.47%, missing previous revenue estimates.
• Shares of Codexis are currently up 3.2%, with the stock trading at $2.93, and institutional investors hold about 78.54% of the company's stock.

Codexis (NASDAQ:CDXS - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Wednesday, August 13th. Analysts expect Codexis to post earnings of ($0.17) per share and revenue of $14.18 million for the quarter. Codexis has set its FY 2025 guidance at EPS.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The company had revenue of $7.54 million during the quarter, compared to analyst estimates of $10.38 million. Codexis had a negative return on equity of 118.47% and a negative net margin of 149.47%. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Stock Performance

CDXS traded down $0.01 during trading on Friday, hitting $2.77. The stock had a trading volume of 860,695 shares, compared to its average volume of 780,368. Codexis has a 12 month low of $1.90 and a 12 month high of $6.08. The firm has a market cap of $229.49 million, a PE ratio of -2.80 and a beta of 2.54. The company has a 50 day simple moving average of $2.65 and a 200-day simple moving average of $2.87. The company has a current ratio of 3.72, a quick ratio of 3.64 and a debt-to-equity ratio of 0.59.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Codexis to a "sell" rating in a research note on Friday, May 16th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Codexis stock. Geode Capital Management LLC raised its holdings in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 2.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,977,869 shares of the biotechnology company's stock after acquiring an additional 52,588 shares during the quarter. Geode Capital Management LLC owned about 2.39% of Codexis worth $4,827,000 as of its most recent SEC filing. Institutional investors and hedge funds own 78.54% of the company's stock.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.